|
|
 |
|
Viewing report
|
|
|
|
Stakeholder Opinions: Traumatic Brain Injury Hormonal therapy generates optimism
Datamonitor, April 2010, Pages: 115
Introduction
There remains no approved pharmacological or cellular treatment to improve the outcome of survivors of traumatic brain injury (TBI). In the past two decades, understanding of the cellular and molecular mechanisms that occur after TBI has grown and a combination of novel therapeutic strategies and approved molecules are presently being examined in clinical trials.
Scope
-Analysis of the patient potential of traumatic brain injury across the seven major markets and several rest of world markets.
-Review of key unmet clinical needs in the treatment of traumatic brain injury and current pipeline treatments.
-Identification of key opportunities and threats facing developers of treatments for traumatic brain injury.
-Insight from six internationally recognized key opinion leaders in the field of spinal cord injuries.
Highlights
The incidence of hospitalized cases of TBI is estimated to be higher than the annual incidence of several medical conditions including some cancer types, epilepsy, HIV/AIDS, multiple sclerosis and spinal cord injury. Therefore, developers of efficacious treatments for TBI stand to benefit from a sizeable patient population.
Despite the high level of unmet need in the treatment of TBI, TBI research is under-funded. The current situation may stem from poor awareness of TBI, pessimism resulting from the relatively high attrition rate in the TBI pipeline and the perception that an efficacious pharmacological treatment for TBI is unattainable.
A sizeable proportion of the clinical candidates are under development as neuroprotective treatments for TBI. The inclusion of two progesterone receptor agonists in the current pipeline is indicative of the rising level of optimism regarding the neuroprotective potential of progesterone in TBI.
Reasons to Purchase
-Quantify the incidence of hospitalized cases of TBI across the seven major pharmaceutical markets and identify key clinical unmet needs.
-Assess the opportunities and threats facing developers in the traumatic brain injury market.
-Utilize pipeline product profiles to identify potential in-licensing opportunities.
Customers who bought this item also bought
Stakeholder Opinions: Spinal Cord Injury - Attractive niche market with multi-billion dollar potential
Nitric Oxide - Therapeutics, Markets and Companies
Endpoints-Clinical Trials in Orphan Diseases - Highest Number of Terminated Trials Focused on Mulitiple Myeloma
Endpoints - Clinical Trials in Dermatology - Inflammatory Lesions Count is the Key Determinant of Success in Acne Vulgaris Clinical Trials
Pipeline and Commercial Insight: Alzheimer's Disease - Market cautiously awaits the first generation of disease-modifying therapies
Clinical Operations: Benchmarking Per-Patient Trial Costs, Staffing and Adaptive Design
Emerging Market for Clinical Trials in Poland - Cost Advantages of Nearly 30% as Compared to the US
Thought Leader Insight & Analysis Report - Multiple Sclerosis Q2 2010
Acute Brain and Spinal Cord Injury: Evolving Paradigms and Management
Pipeline Insight: Epilepsy - Past successes hard to emulate in highly genericized market
|
|
|
|
